inclusion criteria: * willing and able to provide written informed consent * subjects age ≥ 18 * initial sars-cov-2 infection confirmed by pcr test or positive serologies * have findings consistent with interstitial lung disease found on ct scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) * required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation or a history of desaturation below 90% * are at least 30 days from onset of initial sars-cov-2 symptoms * forced vital capacity less than or equal to 90% predicted based on ats/ers criteria or dlco less than or equal to 70% * women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: * willing and able to provide written informed consent * subjects age ≥ 18 * initial sars-cov-2 infection confirmed by pcr test or positive serologies * have findings consistent with interstitial lung disease found on ct scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) * required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation or a history of desaturation below 90% * are at least 30 days from onset of initial sars-cov-2 symptoms * forced vital capacity less than or equal to 90% predicted based on ats/ers criteria or dlco less than or equal to 70% * women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: willing and able to provide written informed consent subjects age ≥ 18 initial sars-cov-2 infection confirmed by pcr test or positive serologies have findings consistent with interstitial lung disease found on ct scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation or a history of desaturation below 90% are at least 30 days from onset of initial sars-cov-2 symptoms forced vital capacity less than or equal to 90% predicted based on ats/ers criteria or dlco less than or equal to 70% women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: willing and able to provide written informed consent subjects age ≥ 18 initial sars-cov-2 infection confirmed by pcr test or positive serologies have findings consistent with interstitial lung disease found on ct scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation or a history of desaturation below 90% are at least 30 days from onset of initial sars-cov-2 symptoms forced vital capacity less than or equal to 90% predicted based on ats/ers criteria or dlco less than or equal to 70% women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: willing and able to provide written informed consent subjects age ≥ 18 initial sars-cov-2 infection confirmed by pcr test or positive serologies have findings consistent with interstitial lung disease found on ct scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation are at least 30 days from onset of initial sars-cov-2 symptoms forced vital capacity less than or equal to 90% predicted based on ats/ers criteria or dlco less than or equal to 70% women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: willing and able to provide written informed consent subjects age ≥ 18 initial sars-cov-2 infection confirmed by pcr test or positive serologies have findings consistent with interstitial lung disease found on ct scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation are at least 30 days from onset of initial sars-cov-2 symptoms forced vital capacity less than or equal to 90% predicted based on ats/ers criteria or dlco less than or equal to 70% women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: - willing and able to provide written informed consent - subjects age > 18 - initial sars-cov-2 infection confirmed by pcr test or positive serologies - have findings consistent with interstitial lung disease found on ct scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) - required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation - are 30 days from onset of initial sars-cov-2 symptoms - forced vital capacity less than or equal to 90% predicted based on ats/ers criteria or dlco less than or equal to 70% - women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: - willing and able to provide written informed consent - subjects age > 18 - initial sars-cov-2 infection confirmed by pcr test or positive serologies - have findings consistent with interstitial lung disease found on ct scan (these may include ground glass opacities, reticulations, traction bronchiectasis, septal thickening, and early honeycombing) - required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation - are 30 days from onset of initial sars-cov-2 symptoms - forced vital capacity less than or equal to 90% predicted based on ats/ers criteria or dlco less than or equal to 70% - women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: - willing and able to provide written informed consent - subjects age > 18 - initial sars-cov-2 infection confirmed by pcr test or positive serologies - have findings consistent with fibrosis found on ct scan (these may include reticulations, traction bronchiectasis, septal thickening, and early honeycombing) - required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation - are 30 days from onset of initial sars-cov-2 symptoms - forced vital capacity less than 80% predicted based on ats/ers criteria or dlco<60% - women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: - willing and able to provide written informed consent - subjects age > 18 - initial sars-cov-2 infection confirmed by pcr test or positive serologies - have findings consistent with fibrosis found on ct scan (these may include reticulations, traction bronchiectasis, septal thickening, and early honeycombing) - required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation - are 30 days from onset of initial sars-cov-2 symptoms - forced vital capacity less than 80% predicted based on ats/ers criteria or dlco<60% - women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: - willing and able to provide written informed consent - subjects age > 18 - initial sars-cov-2 infection confirmed by pcr test or positive serologies within or > 12 weeks of enrollment. sars cov-2 serologies will be confirmed by mount sinai lab prior to enrollment. - have findings consistent with fibrosis found on ct scan (these may include reticulations, traction bronchiectasis, septal thickening, and early honeycombing) - required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation - are 30 days from onset of initial sars-cov-2 symptoms - forced vital capacity less than 80% predicted based on ats/ers criteria - women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib

inclusion criteria: - willing and able to provide written informed consent - subjects age > 18 - initial sars-cov-2 infection confirmed by pcr test or positive serologies within or > 12 weeks of enrollment. sars cov-2 serologies will be confirmed by mount sinai lab prior to enrollment. - have findings consistent with fibrosis found on ct scan (these may include reticulations, traction bronchiectasis, septal thickening, and early honeycombing) - required one of the following after diagnosis with sars-cov-2: supplemental oxygen by nasal cannula, high flow oxygen, non invasive ventilation such as cpap or bipap, or mechanical ventilation - are 30 days from onset of initial sars-cov-2 symptoms - forced vital capacity less than 80% predicted based on ats/ers criteria - women of childbearing potential who agree to use of highly effective contraception during treatment and for three months following the last dose of nintedanib